12:29:18 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2023-11-07 15-10 2023-Q3
2023-08-16 Kvartalsrapport 2023-Q2
2023-05-03 15-10 2023-Q1
2023-03-09 Ordinarie utdelning DEMANT 0.00 DKK
2023-03-08 Årsstämma 2023
2023-02-07 Bokslutskommuniké 2022
2022-11-09 15-10 2022-Q3
2022-08-16 Kvartalsrapport 2022-Q2
2022-05-03 15-10 2022-Q1
2022-03-11 Ordinarie utdelning DEMANT 0.00 DKK
2022-03-10 Årsstämma 2022
2022-02-08 Bokslutskommuniké 2021
2021-08-12 Kvartalsrapport 2021-Q2
2021-03-08 Ordinarie utdelning DEMANT 0.00 DKK
2021-03-05 Årsstämma 2021
2021-02-09 Bokslutskommuniké 2020
2020-08-17 Kvartalsrapport 2020-Q2
2020-03-11 Ordinarie utdelning DEMANT 0.00 DKK
2020-03-10 Årsstämma 2020
2020-02-04 Bokslutskommuniké 2019
2019-08-14 Kvartalsrapport 2019-Q2
2019-03-20 Ordinarie utdelning DEMANT 0.00 DKK
2019-03-19 Årsstämma 2019
2019-02-19 Bokslutskommuniké 2018
2018-08-15 Kvartalsrapport 2018-Q2
2018-03-23 Ordinarie utdelning DEMANT 0.00 DKK
2018-03-22 Årsstämma 2018
2018-02-22 Bokslutskommuniké 2017
2017-08-14 Kvartalsrapport 2017-Q2
2017-05-09 Kvartalsrapport 2017-Q1
2017-03-28 Ordinarie utdelning DEMANT 0.00 DKK
2017-03-27 Årsstämma 2017
2017-02-23 Bokslutskommuniké 2016
2016-11-10 Kvartalsrapport 2016-Q3
2016-08-17 Kvartalsrapport 2016-Q2
2016-05-25 Split DEMANT 1:5
2016-05-10 Kvartalsrapport 2016-Q1
2016-04-08 Ordinarie utdelning DEMANT 0.00 DKK
2016-04-07 Årsstämma 2016
2016-03-01 Bokslutskommuniké 2015
2015-11-12 Kvartalsrapport 2015-Q3
2015-08-14 Kvartalsrapport 2015-Q2
2015-05-07 Kvartalsrapport 2015-Q1
2015-04-10 Ordinarie utdelning DEMANT 0.00 DKK
2015-04-09 Årsstämma 2015
2015-02-26 Bokslutskommuniké 2014
2014-04-10 Ordinarie utdelning DEMANT 0.00 DKK
2013-04-10 Ordinarie utdelning
2012-04-12 Ordinarie utdelning DEMANT 0.00 DKK
2011-04-14 Ordinarie utdelning
2010-04-08 Ordinarie utdelning


ListaLarge Cap Copenhagen
Demant är verksamma inom medicinteknik. Bolaget är specialiserade inom utveckling av hörapparater och hörslingor. Idag innehar bolaget verksamhet på global nivå där produkterna säljs under varierande varumärken. Produkterna nås via bolagets distributörer och försäljningskanaler. Utöver huvudverksamheten bedriver bolaget forskning inom diagnostik för mätning av hörselkvalitén. Bolaget grundades ursprungligen under 1904 och har sitt huvudkontor i Smörum.
2022-03-10 17:20:48

10.3.2022 17:20:45 CET | Demant A/S | Decisions of general meeting

Company announcement no 2022-07

10 March 2022


Decisions of annual general meeting


Today, Demant A/S held its annual general meeting as a hybrid meeting, which took place both as a physical meeting at the company’s headquarters and as a virtual meeting.


In his address, the Chairman of the Board, Niels B. Christiansen, gave an account of the Group’s development in 2021. The report is available on www.demant.com. He said among other things:


“At the beginning of 2021, we had high hopes for the year’s market development, and we are proud to say that not only did we meet our expectations, but we also exceeded them. All in all, 2021 was a fantastic year for Demant where we delivered high organic growth, and our core segment, Hearing Healthcare, delivered a growth rate above the market growth rate. The Group generated record-high revenue of more than DKK 18 billion and the best operating profit (EBIT) ever of more than DKK 3.4 billion.


Both in 2022 and in the years to come, we expect to see growth and to gain further market shares. However, this is only doable through the dedicated efforts of our engaged employees when it comes to ensuring high quality and doing their utmost to provide excellent service to our customers.”


All proposals put forward by the Board of Directors were adopted by the general meeting, implying among others the following decisions:


  • The company’s Annual Report 2021 was approved, and the year’s profit, DKK 2,015 million, will be transferred to the company’s reserves.
  • The Remuneration Report for 2021 was approved.
  • The Director’s fee remains the same as in 2021.
  • Niels B. Christiansen, Niels Jacobsen, Anja Madsen, Sisse Fjelsted Rasmussen and Kristian Villumsen were re-elected members of the Board of Directors.
  • The company’s auditors, Deloitte Statsautoriseret Revisionspartnerselskab, were replaced by PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab (PwC) in compliance with legal requirements in respect of rotation of auditor and accounting firm and with the proposal put forward by the company’s audit committee.
  • The company’s share capital will be reduced by nominally DKK 1,949,819.60, corresponding to the company’s holding of treasury shares at 27 January 2022. The company’s holding of treasury shares was acquired during 2021 as part of the company’s share buy-back scheme. As a result of the capital reduction, article 4.1 of the Articles of Association will be amended no later than four weeks after expiry of the deadline for the filing of claims by creditors, which means that upon expiry of this deadline, it will appear from article 4.1 that the company’s share capital is DKK 46,075,747.00.
  • Until the next ordinary general meeting, the Board was authorised to let the company buy back shares with a nominal value of up to 10% of the share capital.
  • The revised Remuneration Policy, which among other changes implies a change in the remuneration structure for the Executive Board, was approved.


After the general meeting, the Board of Directors elected Niels B. Christiansen Chairman and Niels Jacobsen Deputy Chairman of the Board.


Additionally, after the general meeting and following the approval of the Remuneration Policy, the Board of Directors decided to introduce a share-based programme for the Executive Board as part of their remuneration package as described in the Remuneration Policy.


Rf. Rule 3.8.1 in Nasdaq’s Nordic Main Market Rulebook for Issuers of Shares, the following information is hereby provided about the share-based programme:


Description of the programme


A long-term incentive programme in the form of restricted stock units (RSUs), which will be converted into shares in the company on a 1:1 ratio at vesting.


At the beginning of a one-year performance period, the maximum number of RSUs that will vest at the end of a three-year vesting period is granted.


At the end of the performance period, the number of RSUs will be adjusted based on an assessment of the level of achievement of the performance criteria.


The value of the RSUs cannot be less than 25% of the annual fixed base salary of the Executive Board member in question, and the value cannot be more than 75% of the annual fixed base salary of the Executive Board member.


Please refer to the Remuneration Policy for a more detailed description of the programme.

Performance criteria

Performance criteria are closely aligned with Demant’s strategy and will typically be linked to financial, business and sustainability targets.

Group of persons covered by the

Executive Board as of 1 April 2022

Vesting period

2022-2025, i.e. three years

Performance period

2022, i.e. one year (the first year of the vesting period)

Share price used for grant calculation

DKK 271.70, i.e. the average share price quoted on Nasdaq Copenhagen of the first five trading days following the publication of Demant’s Annual Report 2021.

Total number of RSUs granted


The theoretical
market value of the programme

DKK 20,980,647 based on the share price used for grant calculation and representing the maximum payout to be adjusted based on performance criteria.


Further information:

Søren Nielsen, President & CEO

Phone +45 3917 7300


Other contacts:

René Schneider, CFO

Mathias Holten Møller, Head of Investor Relations

Peter Pudselykke, Investor Relations Officer

Trine Kromann-Mikkelsen, VP Corporate Communications and Relations


About Demant A/S

Demant is a world-leading hearing healthcare group that offers solutions and services to help people with hearing loss connect with the world around them. In every aspect, from hearing devices, hearing implants, diagnostics to audio and video solutions and hearing care all over the world, Demant is active and engaged. Our innovative technologies and know-how help improve people’s health and hear-ing. We create life-changing differences through hearing health.